WuXi AppTec Co., Ltd. Stock

Equities

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
42.92 CNY +3.17% Intraday chart for WuXi AppTec Co., Ltd. +1.71% -41.01%
Sales 2024 * 40.03B 5.52B Sales 2025 * 45.45B 6.27B Capitalization 121B 16.74B
Net income 2024 * 9.82B 1.36B Net income 2025 * 11.62B 1.6B EV / Sales 2024 * 2.73 x
Net cash position 2024 * 11.96B 1.65B Net cash position 2025 * 16.99B 2.34B EV / Sales 2025 * 2.3 x
P/E ratio 2024 *
12.8 x
P/E ratio 2025 *
10.8 x
Employees 41,116
Yield 2024 *
2.25%
Yield 2025 *
2.52%
Free-Float 66.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.17%
1 week+1.71%
Current month-7.06%
1 month-9.57%
3 months-34.93%
6 months-49.13%
Current year-41.01%
More quotes
1 week
41.30
Extreme 41.3
43.30
1 month
41.17
Extreme 41.17
47.89
Current year
41.17
Extreme 41.17
75.38
1 year
41.17
Extreme 41.17
93.56
3 years
41.17
Extreme 41.17
172.49
5 years
31.56
Extreme 31.5604
172.49
10 years
11.02
Extreme 11.0204
172.49
More quotes
Managers TitleAgeSince
Founder 54 00-11-30
Chief Executive Officer 56 00-11-30
Chief Executive Officer 55 15-11-30
Members of the board TitleAgeSince
Chief Investment Officer 61 06-12-31
Director/Board Member 50 16-03-22
Chief Executive Officer 56 00-11-30
More insiders
Date Price Change Volume
24-04-26 42.92 +3.17% 119,709,400
24-04-25 41.6 -0.86% 71,687,640
24-04-24 41.96 -1.57% 70,078,530
24-04-23 42.63 +1.26% 92,119,020
24-04-22 42.1 -0.24% 50,854,780

End-of-day quote Shanghai S.E., April 25, 2024

More quotes
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.; - CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.; - clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.; - other (0.1%). Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
42.92 CNY
Average target price
71.37 CNY
Spread / Average Target
+66.28%
Consensus
  1. Stock Market
  2. Equities
  3. 603259 Stock